Pazopanib Tablet
NDC 51407-872
Product Information
Pazopanib is a ANDA-approved product labeled by Golden State Medical Supply, Inc.. This medication is typically used as a cytochrome p450 2c8 inhibitors [moa]. It is supplied as a gray tablet for oral administration. This product entry covers the primary NDC 51407-872 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Product Characteristics
P200;APO
Code Structure Chart
Product Details
What is NDC 51407-872?
What are the uses of this product?
What are Active Ingredients of this product?
- PAZOPANIB 200 mg/1 - a protein kinase inhibitor
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- PAZOPANIB (UNII: 7RN5DR86CK)
- PAZOPANIB (UNII: 7RN5DR86CK) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- MAGNESIUM STEARATE (UNII: 70097M6I30)
- MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)
- POVIDONE, UNSPECIFIED (UNII: FZ989GH94E)
- SODIUM STARCH GLYCOLATE TYPE A CORN (UNII: AG9B65PV6B)
- HYDROXYPROPYL CELLULOSE (70000 WAMW) (UNII: 66O7AQV0RT)
- METHYLCELLULOSE (100 MPA.S) (UNII: 4GFU244C4J)
- POLYETHYLENE GLYCOL 8000 (UNII: Q662QK8M3B)
- TITANIUM DIOXIDE (UNII: 15FIX9V2JP)
- FERROSOFERRIC OXIDE (UNII: XM0M87F357)
- WATER (UNII: 059QF0KO0R)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 867502 - PAZOPanib 200 MG Oral Tablet
- RxCUI: 867502 - pazopanib 200 MG Oral Tablet
- RxCUI: 867502 - pazopanib (as pazopanib hydrochloride) 200 MG Oral Tablet
Which are the Pharmacologic Classes of this product?
* Please review the full disclaimer at the bottom of this page.